{
    "pmcid": "11481066",
    "qa_pairs": {
        "What challenge did the study highlight regarding the ML predictions and experimental results?": [
            "Discrepancies in predicting protein stability",
            "Inaccurate predictions of binding kinetics",
            "Overestimation of nanobody solubility",
            "Underestimation of nanobody immunogenicity"
        ],
        "What is the primary target for therapeutic antibodies and nanobodies in the SARS-CoV-2 spike protein?": [
            "The receptor binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The fusion peptide"
        ],
        "What method was used to estimate binding free energy changes during molecular dynamics simulations?": [
            "MM/GBSA",
            "FEP+",
            "LIE",
            "TI"
        ],
        "Which machine learning models were used to predict binding affinity changes (\u0394\u0394G) of potential nanobody mutations?": [
            "mCSM-PPI2, MutaBind2, and SAAMBE-3D",
            "AlphaFold, Rosetta, and PyMOL",
            "DeepBind, BindScope, and AffinityNet",
            "TensorFlow, PyTorch, and Keras"
        ],
        "Which nanobody mutant showed stronger binding to the Delta variant S-RBD than the wild-type nanobody?": [
            "H11-H4 nanobody mutant H100Y",
            "H11-D4 nanobody mutant D50Y",
            "H11-B2 nanobody mutant B20Y",
            "H11-F6 nanobody mutant F60Y"
        ]
    }
}